Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President & CEO

Chief Accounting Officer

Chief Financial Officer

Chief Medical Officer

Chief Legal Officer

Chief Business Officer

Chief Scientific Officer

Chief People Officer

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing protei...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2024-02-14	Premium	acquired	Premium	Premium	Premium	Chief Accounting Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	President & CEO
2024-02-14	Premium	acquired	Premium	Premium	Premium	Chief People Officer
2024-02-13	Premium	sold (taxes)	Premium	Premium	Premium	Chief Scientific Officer
2024-02-13	Premium	sold (taxes)	Premium	Premium	Premium	Chief Legal Officer
2024-02-13	Premium	sold (taxes)	Premium	Premium	Premium	Chief People Officer
2024-02-13	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-02-13	Premium	sold (taxes)	Premium	Premium	Premium	Chief Business Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2023-10-02	Premium	acquired	Premium	Premium	Premium	-
2023-10-02	Premium	acquired	Premium	Premium	Premium	-
2023-10-02	Premium	acquired	Premium	Premium	Premium	-
2023-09-18	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-08-30	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer

CCCC - C4 Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CCCC